Chugai And Riken Bio Venture Company To Research Antibody Drugs
This article was originally published in PharmAsia News
Executive Summary
Chugai Pharmaceutical and Chiome Bioscience, a biopharmaceutical venture company established by Riken Institute, announced Dec. 3 that the two will jointly identify monoclonal antibodies against multiple targets selected from a series of disease-associated proteins provided by Chugai. The research will use an autonomously diversifying library system developed by Chiome. Chugai will give Chiome a undisclosed one-time payment and milestone compensations according to research results. (Click here for more - Japanese language
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
England’s NICE Says No To Santhera’s DMD Drug Agamree Due To ‘Unreliable Modeling’
Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.